We also included analysis of the ALK-G1269A mutant, which has so far not been observed as a neuroblastoma mutation but has been described as a more resistant mutation arising in EML4-ALK from NSCLC patients treated with crizotinib [36]. The gene discussed is ALK; the disease is neuroblastoma.